BioSpace News Archive

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved 3DQuorum™ Imaging Technology, powered by Genius AI™. 3DQuorum technology works in tandem with Hologic’s Clarity HD™ high resolution imaging technology to reduce tomosynthesis image volume for radiologists by 66 percent

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the following healthcare investor conferences in November:

Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today reported financial results for the three and nine months ended September 30, 2019.

Raytheon (NYSE: RTN) is using synthetic biology science to create a new method for detecting buried explosives, using bacteria as sensors.

OncoSec Medical Incorporated (“OncoSec”) (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced outcomes from a safety and biomarker analysis on its lead product candidate, TAVO™, at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, 2019, and provided an update on recent clinical developments.

KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of success in drug development, today announced the appointment of Pearl S. Huang, Ph.D. and Theo Melas-Kyriazi to the company’s Board of Directors.

Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced it has completed enrollment for both ongoing global Phase 3 VIOLET clinical trials for VT-1161 ahead of schedule, advancing timelines for the company’s pivotal studies.

Ligand’s revenue grew 250% during the period upon which this list is based.

Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigated in a pivotal Phase 3 global clinical trial, 4WHIM, for the treatment of WHIM syndrome.